Massachusetts Financial Services Co. MA Increases Stake in Novo Nordisk A/S (NYSE:NVO)

Massachusetts Financial Services Co. MA boosted its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 25.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 100,108 shares of the company's stock after purchasing an additional 20,448 shares during the quarter. Massachusetts Financial Services Co. MA's holdings in Novo Nordisk A/S were worth $8,611,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Optimist Retirement Group LLC raised its holdings in shares of Novo Nordisk A/S by 4.3% during the 3rd quarter. Optimist Retirement Group LLC now owns 2,747 shares of the company's stock worth $327,000 after acquiring an additional 112 shares in the last quarter. M. Kulyk & Associates LLC increased its position in Novo Nordisk A/S by 3.9% in the fourth quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company's stock worth $274,000 after purchasing an additional 119 shares during the last quarter. Center for Financial Planning Inc. raised its stake in Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after purchasing an additional 123 shares in the last quarter. Tradewinds Capital Management LLC lifted its position in Novo Nordisk A/S by 2.6% during the fourth quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company's stock valued at $429,000 after purchasing an additional 124 shares during the last quarter. Finally, Exencial Wealth Advisors LLC lifted its position in Novo Nordisk A/S by 0.5% during the fourth quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company's stock valued at $1,987,000 after purchasing an additional 124 shares during the last quarter. Institutional investors own 11.54% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on NVO shares. Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. StockNews.com upgraded Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Monday. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. BMO Capital Markets decreased their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a report on Monday, December 23rd. Finally, Morgan Stanley started coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $145.25.

Novo Nordisk A/S Stock Up 5.8 %

NYSE NVO traded up $3.55 during midday trading on Friday, hitting $64.76. 11,381,677 shares of the company traded hands, compared to its average volume of 5,803,135. Novo Nordisk A/S has a 52 week low of $59.32 and a 52 week high of $148.15. The company's 50-day simple moving average is $77.87 and its 200-day simple moving average is $93.55. The company has a market cap of $290.59 billion, a PE ratio of 19.68, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were given a $0.7874 dividend. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend was Monday, March 31st. Novo Nordisk A/S's dividend payout ratio is presently 49.54%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.